Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin.
BACKGROUND: In four 24-week controlled studies, the antihyperglycaemic efficacy of saxagliptin was demonstrated in patients with type 2 diabetes mellitus as add-on therapy to glyburide, a thiazolidinedione, or metformin, and when used in initial combinati.....